BR112018068671A2 - anticorpos monoclonais neutralizantes para il-25 e usos dos mesmos - Google Patents

anticorpos monoclonais neutralizantes para il-25 e usos dos mesmos

Info

Publication number
BR112018068671A2
BR112018068671A2 BR112018068671A BR112018068671A BR112018068671A2 BR 112018068671 A2 BR112018068671 A2 BR 112018068671A2 BR 112018068671 A BR112018068671 A BR 112018068671A BR 112018068671 A BR112018068671 A BR 112018068671A BR 112018068671 A2 BR112018068671 A2 BR 112018068671A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibodies
neutralizing monoclonal
neutralizing
present
binding molecules
Prior art date
Application number
BR112018068671A
Other languages
English (en)
Inventor
Lyles Jackson Crystal
BARTLETT Nathan
A Shimkets Richard
Vincent Thomas
Luo Yonghua
Original Assignee
Abeome Corp
Lyles Jackson Crystal
BARTLETT Nathan
A Shimkets Richard
Vincent Thomas
Luo Yonghua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abeome Corp, Lyles Jackson Crystal, BARTLETT Nathan, A Shimkets Richard, Vincent Thomas, Luo Yonghua filed Critical Abeome Corp
Publication of BR112018068671A2 publication Critical patent/BR112018068671A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção revela composições e métodos relacionados com moléculas de ligação de il -25.
BR112018068671A 2016-03-16 2017-03-09 anticorpos monoclonais neutralizantes para il-25 e usos dos mesmos BR112018068671A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309135P 2016-03-16 2016-03-16
PCT/US2017/021578 WO2017160587A1 (en) 2016-03-16 2017-03-09 Neutralizing monoclonal antibodies to il-25 and uses thereof

Publications (1)

Publication Number Publication Date
BR112018068671A2 true BR112018068671A2 (pt) 2019-07-30

Family

ID=59852393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068671A BR112018068671A2 (pt) 2016-03-16 2017-03-09 anticorpos monoclonais neutralizantes para il-25 e usos dos mesmos

Country Status (12)

Country Link
US (1) US11492397B2 (pt)
EP (1) EP3430046A4 (pt)
JP (2) JP7140397B2 (pt)
KR (1) KR102477922B1 (pt)
CN (2) CN115010808A (pt)
AU (1) AU2017234528B2 (pt)
BR (1) BR112018068671A2 (pt)
CA (1) CA3018058A1 (pt)
EA (1) EA201892096A1 (pt)
IL (1) IL261802B2 (pt)
MX (1) MX2018011244A (pt)
WO (1) WO2017160587A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892096A1 (ru) * 2016-03-16 2019-08-30 Эйбоум Корпорейшн Нейтрализующие моноклональные антитела к il-25 и их применение
EP3883965A4 (en) * 2018-11-19 2022-10-12 Suzhou Kanova Biopharmaceutical Co., Ltd. ANTI-IL-25 ANTIBODIES AND THEIR USE
WO2023060144A1 (en) * 2021-10-05 2023-04-13 Lanier Biotherapeutics Monoclonal antibodies to il-25 and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2007044450A2 (en) 2005-10-06 2007-04-19 Baylor Research Institute Compositions and methods for the treatment of cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
NZ590131A (en) 2008-07-08 2012-10-26 Oncomed Pharm Inc Notch-binding agents and antagonists and methods of use thereof
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
CN102245767B (zh) 2008-10-31 2013-09-18 东丽株式会社 人cxcl1蛋白质的免疫学测定方法
US8574582B2 (en) 2008-10-31 2013-11-05 Janssen Biotech, Inc. Methods for mediating fibrotic response
DK2462161T3 (en) * 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
WO2011054007A1 (en) * 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
KR101830181B1 (ko) * 2010-03-30 2018-02-20 얀센 바이오테크 인코포레이티드 인간화 il-25 항체
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
AU2012273954A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2780354A4 (en) * 2011-11-16 2015-06-24 Oncomed Pharm Inc HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE
CA2898472C (en) * 2013-02-15 2023-03-07 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
EA201892096A1 (ru) * 2016-03-16 2019-08-30 Эйбоум Корпорейшн Нейтрализующие моноклональные антитела к il-25 и их применение

Also Published As

Publication number Publication date
AU2017234528B2 (en) 2023-09-28
CN109563162B (zh) 2022-05-24
JP2019521132A (ja) 2019-07-25
CN109563162A (zh) 2019-04-02
EP3430046A1 (en) 2019-01-23
KR102477922B1 (ko) 2022-12-14
IL261802B2 (en) 2024-01-01
EA201892096A1 (ru) 2019-08-30
CN115010808A (zh) 2022-09-06
WO2017160587A1 (en) 2017-09-21
US20200291105A1 (en) 2020-09-17
AU2017234528A8 (en) 2018-11-29
KR20190039469A (ko) 2019-04-12
EP3430046A4 (en) 2019-10-23
US11492397B2 (en) 2022-11-08
IL261802A (en) 2018-10-31
JP7140397B2 (ja) 2022-09-21
AU2017234528A1 (en) 2018-11-08
JP2022184857A (ja) 2022-12-13
IL261802B1 (en) 2023-09-01
CA3018058A1 (en) 2017-09-21
MX2018011244A (es) 2019-05-30

Similar Documents

Publication Publication Date Title
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
BR112018002432A2 (pt) anticorpos de ligação à il-8 e usos dos mesmos
ECSP18000844A (es) Anticuerpos de unión a tau
CR20180234A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DK3356401T3 (da) Bindingsmolekyler med modificeret j-kæde
BR112018010360A2 (pt) fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
BR112016020112A2 (pt) anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica
BR112017002646A2 (pt) proteínas de fusão da imunoglobulina sirp-alfa
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112016014731A2 (pt) Anticorpos anti-baff
ECSP18000887A (es) Anticuerpos de unión a tau
BR112017009297A2 (pt) anticorpos antifator de complemento c1q humanizados e usos dos mesmos
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements